Mona Kargar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mona Kargar has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Molouk Hadjibabaie
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications- Alireza Ahmadvand
School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia
3 shared publications Kheirollah Gholami
Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications- Kheirollah Gholami
Tehran University of Medical Sciences
3 shared publications Aarefeh Jafarzadeh Kohneloo
Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences School of Public Health, Tehran, Iran; Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsNiloofar Khoshnam-Rad
Department of Clinical Pharmacy, Tehran University of Medical Sciences School of Pharmacy, Tehran, Iran
2 shared publications
Latest Publications
- 16 October 2026
- Published by Taylor & Francis in Postgraduate Medicine
- p. 1-10
Changes in intravenous pantoprazole utilization following two sequential interventions in a tertiary referral hospital
- 16 October 2026
- Published by Taylor & Francis in Postgraduate Medicine
- p. 1-10
Changes in intravenous pantoprazole utilization following two sequential interventions in a tertiary referral hospital
- 6 September 2024
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 32 (2) , 665-673
Lipid management strategies for diabetic patients align with an evidence-based guideline
Background Diabetes mellitus (DM) increases the risk of cardiovascular diseases (CVD) significantly. Statins are recommended for all diabetic patients aged ≥ 40 years to alleviate this risk. Objectives This study aimed to determine the status of the implementation of the recommendations of lipid management strategies for diabetic patients. Methods In this cross-sectional study, 500 patients with DM, aged ≥ 40 referring to a public pharmacy with at least one diabetic medication in their prescription, were enrolled. Patients’ demographics, lipid panel data, medications, personal and family history of atherosclerotic cardiovascular disease (ASCVD), and risk factors for ASCVD were documented. The appropriateness of stain dosing intensity was judged based on the American Diabetes Association (ADA) guideline. Results The mean ± SD of the age of patients was 61.39 ± 10.49 years. Among patients, 238 (47.6) were men. More than half of the patients were subject to receiving primary prevention (59.8%, n = 299). For 80.8% (n = 404) of patients, a statin, most frequently atorvastatin (61.8%), was prescribed. The appropriate statin dose based on the guideline for 470 patients (94%), was high-intensity statin. In 70.6% (n = 353) of patients, lipid management was not in accordance with the guideline. Patients with ASCVD were more likely to receive the statins and the appropriate doses compared to patients without ASCVD (p-value < 0.001). Conclusion Despite a relatively high percentage of patients who received statins, the lipid management in most patients was not in accordance with the guideline. The profound problem was the suboptimal dosage of statins. Investigating the reasons and barriers of the appropriate management can be helpful. Additionally, since patients without ASCVD who should receive statins for primary prevention were significantly less likely to receive statins and evidence-based doses, more attention is needed for this population. Graphical Abstract
- 6 September 2024
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 32 (2) , 665-673
Lipid management strategies for diabetic patients align with an evidence-based guideline
Background Diabetes mellitus (DM) increases the risk of cardiovascular diseases (CVD) significantly. Statins are recommended for all diabetic patients aged ≥ 40 years to alleviate this risk. Objectives This study aimed to determine the status of the implementation of the recommendations of lipid management strategies for diabetic patients. Methods In this cross-sectional study, 500 patients with DM, aged ≥ 40 referring to a public pharmacy with at least one diabetic medication in their prescription, were enrolled. Patients’ demographics, lipid panel data, medications, personal and family history of atherosclerotic cardiovascular disease (ASCVD), and risk factors for ASCVD were documented. The appropriateness of stain dosing intensity was judged based on the American Diabetes Association (ADA) guideline. Results The mean ± SD of the age of patients was 61.39 ± 10.49 years. Among patients, 238 (47.6) were men. More than half of the patients were subject to receiving primary prevention (59.8%, n = 299). For 80.8% (n = 404) of patients, a statin, most frequently atorvastatin (61.8%), was prescribed. The appropriate statin dose based on the guideline for 470 patients (94%), was high-intensity statin. In 70.6% (n = 353) of patients, lipid management was not in accordance with the guideline. Patients with ASCVD were more likely to receive the statins and the appropriate doses compared to patients without ASCVD (p-value < 0.001). Conclusion Despite a relatively high percentage of patients who received statins, the lipid management in most patients was not in accordance with the guideline. The profound problem was the suboptimal dosage of statins. Investigating the reasons and barriers of the appropriate management can be helpful. Additionally, since patients without ASCVD who should receive statins for primary prevention were significantly less likely to receive statins and evidence-based doses, more attention is needed for this population. Graphical Abstract
- 5 October 2022
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 90 (5) , 427-428
Effects of vitamin E in preventing taxane‑induced peripheral neuropathy
- 5 October 2022
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 90 (5) , 427-428
Effects of vitamin E in preventing taxane‑induced peripheral neuropathy
- 19 June 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (4) , 747-748
Low Dose Antipsychotics for the Treatment of Delirium in Hospitalized Elderly Patients and Their Effects on QTc Interval
- 19 June 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (4) , 747-748
Low Dose Antipsychotics for the Treatment of Delirium in Hospitalized Elderly Patients and Their Effects on QTc Interval
- 15 May 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (5) , 449-450
Depression, Anxiety, and Quality of Life in Hepatitis C Patients Treated with Direct-Acting Antiviral Agents
Cite this article as: Khoshnam-Rad N, Jafarzadeh Kohneloo A, Kargar M. Depression, anxiety, and quality of life in hepatitis C patients treated with direct-acting antiviral agents. Turk J Gastroenterol. 2022;33(5):449-450.
- 15 May 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (5) , 449-450
Depression, Anxiety, and Quality of Life in Hepatitis C Patients Treated with Direct-Acting Antiviral Agents
Cite this article as: Khoshnam-Rad N, Jafarzadeh Kohneloo A, Kargar M. Depression, anxiety, and quality of life in hepatitis C patients treated with direct-acting antiviral agents. Turk J Gastroenterol. 2022;33(5):449-450.
- Open Access
- 28 December 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (12) , e14951
Hepatoprotective effects of metformin in hepatitis C virus‐infected adolescents with beta thalassaemia major
Click on the article title to read more.
- 28 December 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (12) , e14951
Open AccessHepatoprotective effects of metformin in hepatitis C virus‐infected adolescents with beta thalassaemia major
Click on the article title to read more.
- 16 March 2021
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1427-1428
Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?
- 16 March 2021
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1427-1428
Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?
- 24 February 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (3) , 778-779
Comparison of the effect of different methods of cyclosporine infusion on transplant-related outcomes in allogeneic transplant recipients
- 24 February 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (3) , 778-779
Comparison of the effect of different methods of cyclosporine infusion on transplant-related outcomes in allogeneic transplant recipients
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 57
Drug-drug interactions and potentially inappropriate medications among elderly outpatients
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 57
Open AccessDrug-drug interactions and potentially inappropriate medications among elderly outpatients
- 21 October 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 42 (6) , 1521-1523
Drug survival of infliximab and adalimumab in inflammatory bowel disease
- 21 October 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 42 (6) , 1521-1523
Drug survival of infliximab and adalimumab in inflammatory bowel disease